Sanofi Consumer Healthcare’s Q3 profit jumps 40% to ₹62.9 crore, revenue grows 46% to ₹233.9 crore
/ 2 min read
Sanofi Consumer Healthcare’s Q3 profit jumps 40% to ₹62.9 crore, revenue grows 46% to ₹233.9 crore
Sanofi Consumer Healthcare India reported a significant 40% increase in Q3 profit to ₹62.9 crore, with revenue surging 46% to ₹233.9 crore, driven by a 20% rise in domestic sales and a remarkable tenfold increase in exports. The company successfully reintroduced previously recalled products, contributing to its robust performance.
This summary is AI-generated, and Fortune India is not responsible for its content or any associated copyright issues.
Sanofi Consumer Healthcare India, a distinct entity following its demerger from Sanofi India, saw a robust increase in its domestic business, supported by export growth.
Sanofi Consumer Healthcare India Limited said on Thursday that its third-quarter profit jumped 40% to ₹62.9 crore and revenue grew 46% to ₹233.9 crore, aided by a 20% increase in domestic sales.
The export sales of the Indian unit of the French multinational pharmaceutical and healthcare company recorded an increase that surpassed the tenfold mark, on account of a lower base. “The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year,” said Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India Limited, in a statement.
For the nine-month period, Sanofi Consumer Healthcare India's revenue was ₹672.4 crore, a growth of 13% from the year-ago period. Its domestic sales grew marginally by 1%, and export sales increased by 96% due to a lower base. However, Sanofi Consumer Healthcare said that the quarter and nine months figures are not directly comparable due to the demerger and voluntary recall of certain variants of key brands in the domestic market.
Sanofi Consumer Healthcare India, during the previous year, had voluntarily decided to recall Depura Adult, Depura Kids, Allegra Suspension and Combiflam Suspension from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the Company has successfully relaunched Depura Adult and Combiflam Suspension during the quarter ended March 2025 and June 2025, respectively. Allegra Suspension and Depura Kids were relaunched in quarter ended September 2025. To that effect, the results are not comparable with the corresponding quarters and nine months, as the recall had an impact on the domestic business.
Sanofi Consumer Healthcare India had emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June of last year. In alignment with Sanofi’s global strategy, Sanofi Consumer Healthcare India is now operating independently, with a dedicated focus on the consumer healthcare sector.
The shares of Sanofi Consumer Healthcare India, at the time of publishing, were up 7.34% and trading at ₹4999 apiece.